A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)
Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl*
Dive into the research topics of 'A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)'. Together they form a unique fingerprint.
Keyphrases
Medicine and Dentistry
Pharmacology, Toxicology and Pharmaceutical Science